1.Dattani MT, Robinson IC. The molecular basis for developmental disorders of the pituitary gland in man. Clin Genet. 2000; 57: 337-46.
2.Tsuda M, Takahashi S et al. CT and MR imaging of craniopharyngioma. Eur Radiol 1997; 7: 464:469
3.Carmel PW, Antunes JL, Chang CH. Craniopharyngioma in children. Neurosurgery 1982; 11: 382-9.
4.Bunin GR, Surawicz TS, Witman PA, Preston-Martin S, Davis F, Bruner JM. 1998 The descriptive epidemiology of craniopharyngioma. J Neurosurg. 89:547–551.
5.Atlas SW. Magnetic resonance imaging of the brain and spine. Raven Press, new York 1991.
6.Akimuta T, Karleda H, et al. Infrasellar craniopharyngioma. Neuroradiology 1989; 31: 180-3.
7.Hillman TH, Peyster RG, et al. Infrasellar craniopharyngiomas. J Comput Assist Tomogr 1988; 12: 702-4.
8.Lafferty AR, Chrousos GP. Pituitary tumors in children and adolescents. J Clin Endocrinol Metab 1999; 84: 4317-4323
9.Sklar CA. 1994 Craniopharyngioma: endocrine abnormalities at presentation. Pediatr Neurosurg. 21(Suppl 1):18–20.
10.Thomsett MJ, Conte FA, Kaplan SL, Grumbach MM. 1980 Endocrine and neurologic outcome in childhood craniopharyngioma: review of effect of treatment in 42 patients. J Pediatr. 97:728–735
11.Ghirardello S, Hopper N, Albanese A, Maghnie M.Diabetes insipidus in craniopharyngioma: postoperative management of water and electrolyte disorders. J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:413-21.
12.Freeman M, Kessler R, et al. Craniopharyngioma: CT and MR imaging in nine cases. J Comput Assist Tomogr 1987; 5: 810-4.
13.Pusey E, Kortman KE, et al. MR of craniopharyngiomas: tumor delineation and characterization. AJNR 1987; 8: 439-444.
14.Braun IF, Pinto RS, Epstein F. Dense cystic craniopharyngiomas. AJNR 1982; 3: 139-141.
15.Scott RM, Hetelekidis S, Barnes PD, Goumnerova L, Tarbell NJ. 1994 Surgery, radiation, and combination therapy in the treatment of childhood craniopharyngioma–a 20-year experience. Pediatr Neurosurg. 21(Suppl 1):75–81.
16.Sanford RA. 1994 Craniopharyngioma: results of survey of the American Society of Pediatric Neurosurgery. Pediatr Neurosurg. 21(Suppl 1):39–43.
17.Fahlbusch R, Honegger J, Paulus W, Huk W, Buchfelder M. 1999 Surgical treatment of craniopharyngiomas: experience with 168 patients. J Neurosurg. 90:237–250.
18.Hetelekidis S, Barnes PD, Tao ML, et al. 1993 20-year experience in childhood craniopharyngioma. Int J Radiat Oncol Biol Phys. 27:189–195.
19.Sklar CA. 1994 Craniopharyngioma: endocrine sequelae of treatment. Pediatr Neurosurg. 21(Suppl 1):120–123.
20.Ahmet A, Blaser S, Stephens D, Guger S, Rutkas JT, Hamilton J. Weight gain in craniopharyngioma--a model for hypothalamic obesity. J Pediatr Endocrinol Metab. 2006; 19: 121-7
21.Muller HL, Muller-Stover S, Gebhardt U, Kolb R, Sorensen N, Handwerker G. Secondary narcolepsy may be a causative factor of increased daytime sleepiness in obese childhood craniopharyngioma patients.J Pediatr Endocrinol Metab. 2006; 19 Suppl 1:423-9.
22.Luu QT, Loredo LN, Archambeau JO, Yonemoto LT, Slater JM, Slater JD. Fractionated proton radiation treatment for pediatric craniopharyngioma: preliminary report. Cancer J. 2006 Mar-Apr;12: 155-9.
23.Sands SA, Milner JS, Goldberg Jet al. Quality of life and behavioral follow-up study of pediatric survivors of craniopharyngioma. J Neurosurg. 2005; 103 (4 Suppl): 302-11.
24.Odom GL, Davis CH, Woodhall B. Brain tumors in children: Clinical analysis in 164 cases. Pediatrics 1956; 18:856-869.
25.Mindermann T, Wilson CB. Pediatric pituitary adenomas. Neurosurgery 1995; 36 :259-269.
26.Colao A, Loche S, Cappabianca P, de Divitiis E, Lombardi G. Pituitary adenomas in children and adolescents. Clinical presentation, diagnosis and therapeutical strategies. The Endocrinologist 2000; 10: 314-320.
27.Boop FA, Teo C, Pihoker K. Pediatric pituitary tumors. In: Krisht AF, Tindall GT (eds) Comprehensive management of pituitary disorders. Lippincott Williams & Wilkins, Hagerstown, 1999; pp 315-326.
28.Partington MD, Dudley HD, Laws ER, Scheithauer BW. Pituitary adenomas in childhood and adolescence. Results of transsphenoidal surgery. J Neurosurg 1994; 80 :209-216.
29.Ludecke DK, Herrmann HD, Schulte FJ. Special problems with neurosurgical treatment of hormone-secreting pituitary adenomas in children. Prog Exp Tumor Res 1987;30:362-70.
30.Gold EB. Epidemiology of pituitary adenomas. Epidemiol Rev 1981; 3: 163-183.
31.Haddad SF, VanGilder JC, Menezes AH. Pediatric pituitary tumors. Neurosurgery 1991; 29:509-514.
32.Kane LA, Leinung MC, Scheithauer BW, et al. Pituitary adenomas in childhood and adolescence. J Clin Endocrinol Metab 1994; 79: 1135-1140.
33.Artese R, D’Osvaldo DH, Molocznik I, et al. Pituitary tumors in adolescent patients. Neurol Res 1998;20:415-417.
34.Avramides A, Karapiperis A, Triantafyllidou E, Vayas S, Moshidou A, Vyzantiadis A. TSH-secreting pituitary macroadenoma in an 11-year-old girl. Acta Paediatr 1992;81:1058-1060.
35.Dyer EH, Civit E, Visot A, Delalande O, Derome P. Transsphenoidal surgery for pituitary adenomas in children. Neurosurgery 1994; 34:207-212.
36.Maira G, Anile C. Pituitary adenomas in childhood and adolescence. Can J Neurol Sci 1990; 17: 83-87.
37.Richmond IL, Wilson CB. Pituitary adenomas in childhood and adolescence. J Neurosurg 1978; 49: 163-168.
38.Dissaneevate P, Warne GL. Hyperprolactinaemia and pituitary adenomas in adolescence. J Pediatr Endocrinol Metab 1998; 11:531-41.
39.Colao A, Loche S, Cappa M, et al. Prolactinomas in children and adolescents. Clinical presentation and long term follow-up. J Clin Endocrinol Metab 1998; 83:2777-2780.
40.Cannavò S, Venturino M, Curto L, De Menis E, D'Arrigo C, Tita P, Billeci D, Trimarchi F. Clinical presentation and outcome of pituitary adenomas in teenagers. Clin Endocrinol (Oxf). 2003; 58(4):519-27
41.Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006 May 26; [Epub ahead of print]
42.Schlechte J, El-Khoury G, Kathol M, Walkner L. Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1987; 64; 1021-1026.
43.Biller BMK, Baum HBA, Rosenthal DI, Saxe VC, Charpie PM, Klibanski A. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1992; 75: 692-7.
44.Di Somma C, Colao A, Di Sarno A, et al. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 1998; 83: 807-813.
45.Colao A, Di Somma C, Loche S, et al. Prolactinomas in children and adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol 2000; 52: 319-328
46.Tyson D, Reggiardo D, Sklar C, David R. Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy. Am J Dis Child 1993; 147:1057-1061.
47.Blackwell RE, Younger BJ. Long-term medical therapy and follow up of pediatric adolescent patients with prolactin-secreting macroadenomas. Fertil Steril 1986; 45 :713-716.
48.Howlett TA, Wass JAH, Grossman A, et al. Prolactinomas presenting as primary amenorrhoea and delayed or arrested puberty: response to medical therapy. Clin Endocrinol. 1989; 30:131-140.
49.Dalzell GW, Atkinson AB, Carson PJ, Sheridan B. Normal growth and pubertal development during bromocriptine treatment for a prolactin-secreting pituitary macroadenoma. Clin Endocrinol 1987; 26:169-172.
50.Knoepfelmacher M, Gomes MC, Melo ME, Mendonca BB. Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma. Pituitary. 2004;7(2):83-7.
51.Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G 2003 Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023-33
52.Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 1998; 19:647-672.
53.Magiakou MA, Mastorakos G, Gomez MT, Rose SR, Chrousos GP. Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing’s disease before and after surgical cure. J Clin Endocrinol Metab 1994; 78:131-137.
54.Baron J, Klein KO, Colli MJ, et al. Catch-up growth after glucocorticoid excess: a mechanism intrinsic to the growth plate. Endocrinology 1994; 135:1367-1371.
55.Magiakou MA, Mastorakos G, Oldfield EH, et al. Cushing’s syndrome in children and adolescents. Presentation, diagnosis, and therapy. N Engl J Med 1994; 331:629-636.
56.Weber A, Trainer PJ, Grossman AB, et al. Investigation, management and therapeutic outcome in 12 cases of childhood and adolescent Cushing’s syndrome. Clin Endocrinol 1995; 43:19-28.
57.Devoe DJ, Miller WL, Conte FA, et al. Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing’s disease. J Clin Endocrinol Metab 1997; 82:3196-3202.
58.Leong GM, Mercado-Asis LB, Reynolds JC, Hill SC, Oldfield EH, Chrousos GP. The effect of Cushing’s disease on bone mineral density, body composition, growth, and puberty: a report of an identical adolescent twin pair. J Clin Endocrinol Metab 1996; 81:1905-1911.
59.Dempster D, Arlot M, Meunier P. Mean wall thickness and formation period of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int 1983; 35:410-417.
60.Di Somma C, Pivonello R, Loche S, et al. Severe impairment of bone mass and turnover in Cushing’s disease: comparison between childhood-onset and adulthood onset disease. Clin Endocrinol 2002; 56: 153-8
61.Di Somma C, Pivonello R, Loche S, et al. Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing’s disease. Clin Endocrinol 2003; 58(3):302-8.
62.Bressot C, Meunier P, Chapuy M, Lejeune E, Edouard C, Darby A. Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis. Metab Bone Dis Relat Res 1979; 1:303-311.
63.Delany A, Gabbitas B, Canalis E. Cortisol down-regulates osteoblast α1 (I) procollagen mRNA by trascriptional and post-trascriptional mechanism. J Cell Biochem 1995; 57:488-494.
64.Canalis E. Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 1996; 81: 3441-3447.
65.Delany A, Gabbitas B, Canalis E. Cortisol down-regulates osteoblast α1 (I) procollagen mRNA by trascriptional and post-trascriptional mechanism. J Cell Biochem 1995; 57:488-494.
66.Buzi F, Corna A, Pilotta A, et al. Loperamide test: a simple and highly specific screening test for hypercortisolism in children and adolescents. Acta Paediatr 1997; 66:1177-1180.
67.Kunvar S, Wilson CB. Pediatric pituitary adenomas. J Clin Endocrinol Metab 1999; 84:4385-4389.
68.Colao A, Faggiano A, Pivonello R, Pecori Giraldi F, Cavagnini F, Lombardi G, and The Study Group of the Italian Endocrinology Society on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. Inferior petrosal sinus sampling in the differential diagnosis of Cushing’s syndrome: Results of an Italian multicentre study. Eur J Endocrinol 2001; 144: 499-507
69.Lienhardt A, Grossman AB, Dacie JE, et al. Relative contributions of inferior petrosal sinus sampling and pituitary imaging in the investigation of children and adolescents with ACTH-dependent Cushing’s syndrome. J Clin Endocrinol Metab 2001; 86:5711-5714.
70.Oldfield EH, Doppman JL, Nieman LK, et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med 1991; 325:897-905.
71.Styne DM, Grumbach MM, Kaplan SA, Wilson CB, Conte FA. Treatment of Cushing’s disease in childhood and adolescence by transphenoidal microadenomectomy. N Engl J Med 1984; 310:889-893.
72.Buchfelder M, Fahlbusch R. Neurosurgical treatment of Cushing’s disease in children and adolescents. Acta Neurochirurg 1985; suppl 35:101-103.
73.Fahlbush R, Honegger J, Buchfelder M. Neurosurgical management of Cushing’s disease in children. In: Savage MO, Bourguignon JP, Grossman AB (Eds), Frontiers in Pediatric Neuroendocrinology 1994; 68-72.
74.Massoud AF, Powell M, Williams RA, Hindmarsh PC, Brook CGD. Transsphenoidal surgery for pituitary tumours. Arch Dis Child 1997; 76:398-404.
75.Leinung MC, Kane LA, Scheithauer BW, Carpenter PC, Laws ER Jr, Zimmerman D. Long term follow-up of transsphenoidal surgery or the treatment of Cushing’s disease in childhood. J Clin Endocrinol Metab 1995; 80:2475-2479.
76.Storr HL, Afshar F, Matson M, et al. Factors influencing cure by trans-sphenoidal selective adenomectomy in paediatric Cushing’s disease. Eur J Endocrinol 2005; 152: 825-33.
77.Clayton RN, Stewart PM, Shalet SM, Wass JA 1999 Pituitary surgery for acromegaly. Should be done by specialists. BMJ 319:588-589.
78.Magiakou MA, Mastorakos G, Chrousos GP. Final stature in patients with endogenous Cushing’s syndrome. J Clin Endocrinol Metab 1994; 79:1082-1085.
79.Johnston LB, Grossman AB, Plowman PN, Besser GM, Savage MO. Normal final height and apparent cure after pituitary irradiation for Cushing’s disease in childhood: long-term follow-up of anterior pituitary function. Clin Endocrinol 1998; 48:663-667.
80.Lebrethon MC, Grossman AB, Afshar F, Plowman PN, Besser GM, Savage MO. Linear growth and final height after treatment for Cushing's disease in childhood J Clin Endocrinol Metab 2000; 85: 3262-5
81.Davies JH, Storr HL, Davies K, Monson JP, Besser GM, Afshar F, Plowman PN, Grossman AB, Savage MO.Final adult height and body mass index after cure of paediatric Cushing's disease. Clin Endocrinol (Oxf). 2005; 62: 466-72.
82.Friedman RB, Oldfield EH, Nieman LH, et al. Repeat trans-sphenoidal surgery for Cushing’s disease. J Neurosurg 1989; 71:520-527.
83.Estrada J, Boronat M, Mielgo M, et al. The long term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing’s disease. N Engl J Med 1997; 336: 172-177.
84.Jennings AS, Liddle GW, Orth DN. Results of treating childhood Cushing’s disease with pituitary irradiation. N Engl J Med 1977; 297:957-962.
85.Greening JE, Brain CE, Perry LA, et al. Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing's disease. Horm Res. 2005; 64: 140-3.
86.Merke DP, Giedd JN, Keil MF, et al. Children experience cognitive decline despite reversal of brain atrophy one year after resolution of Cushing syndrome. J Clin Endocrinol Metab. 2005; 90: 2531-6
87.Colao A, Lombardi G. GH and PRL excess. Lancet 1998; 352: 1455-1461.
88.Eugster EA, Pescovitz OH. Gigantism. J Clin Endocrinol Metab 1999; 84: 4379-3484.
89.Sotos JF. Overgrowth, section II. Clin Pediatr. 1996; 35: 579–590.
90.Whitehead EM, Shalet SM, Davies D, Enoch BA, Price DA, Beardwell CG. Pituitary gigantism: a disabling condition. Clin Endocrinol. 1982; 17:271–277
91.Colao A, Merola B, Ferone D, Lombardi G. Acromegaly. J Clin Endocrinol Metab 1997;82:2777-2781.
92.Melmed S. Acromegaly and cancer: not a problem. J Clin Endocrinol Metab 2001; 86: 2929-2934.
93.Jenkins PJ, Besser M. Acromegaly and cancer: a problem. J Clin Endocrinol Metab 2001; 86: 2935-2941.
94.Barkan A. Acromegalic arthropathy and sleep apnea. J Endocrinol 1997;155:S41-44.
95.Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004; 25: 102-152
96.Bondanelli M, Bonadonna S, Ambrosio MR, et al. Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism. Metabolism. 2005; 54: 1174-80.
97.Lamberts SWJ, van der Lely AJ, de Herder WW. Clinical and medical diagnosis of acromegaly. Metabolism 1995;44(suppl.1):15-17.
98.Blumberg DL, Sklar CA, David R, Rothenberg S, Bell J. Acromegaly in an infant. Pediatrics 1989;83:998-1002.
99.Kaltsas GA, Mukherjee JJ; Jenkins PJ, et al. Mestrual irregularity in women with acromegaly. J Clin Endocrinol Metab 1999; 84: 2731-2735.
100.Alvi NS, Kirk JM. Pituitary gigantism causing diabetic ketoacidosis. J Pediatr Endocrinol Metab 1999; 12: 907-909
101.Giustina A, Barkan A, Casanueva FF, et al. 2000 Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526-529.
102.de Herder WW, van der Lely AJ, Janssen JAMJL, et al. IGFBP-3 is a poor parameter for assessment of clinical activity in acromegaly. Clin Endocrinol 1995; 43:501-515.
103.Marzullo P, Di Somma C, Pratt KL, et al.Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults. J Clin Endocrinol Metab 2001;86:3001-8
104.Ng LL, Chasalow FI, Escobar O, Blethen SL. Growth hormone isoforms in a girl with gigantism. J Pediatr Endocrinol Metab 1999; 12: 99-106.
105.Chapman IM, Hartan ML, Straume M, Johnson ML, Veldhuis JD, Thorner MO. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than in women. J Clin Endocrinol Metab 1994;78:1312-1319.
106.Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JR, Shalet SM. The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin Endocrinol 1998; 49: 653-657.
107.Ahmed S, Eldsheikh, Stratton IM, Page RC, Adams, CB, Wass JA. Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol 1999; 50: 561-567.
108.Yamada S, Aibat T, Takada K, et al. Retrospective analysis of long-term surgical results in acromegaly: preoperative and post-operative factors predicting outcome. Clin Endocrinol 1996;45:291-298.
109.Sheaves R, Jenkins P, Blackburn P, et al. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol 1996;45:407-13.
110.Abe T, Tara LA, Lüdecke DK. Growth hormone-secreting pituitary adenomas in childhood and adolescence: features and results of transnasal surgery. Neurosurgery 1999; 45: 1-10.
111.Ferone D, Colao A, van der Lely A-J, Lamberts SWJ. Pharmacotherapy or surgery as primary treatment for acromegaly? Drugs 2000; 17: 81-92.
112.Gelber SJ, Heffez DS, Donohoue PA. Pituitary gigantism caused by growth hormone excess from infancy. J Pediatr 1992; 120: 931-4.
113.Yoshida T, Shimatsu A, Sakane N, et al. Growth hormone (GH) secretory dynamics in a case of acromegalic gigantism associated with hyperprolactinemia: nonpulsatile secretion of GH may induce elevated insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 levels. J Clin Endocrinol Metab 1996; 81: 310-3.
114.Eastman RC, Gorden P, Glatstein E, et al. Radiation therapy for acromegaly. Endocrinol Metab Clin North Am 1992;21:693-712.
115.Barkan A, Halasz I, Dornfeld KJ, et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 1997;82:3187-3191.
116.Thalassinos NC, Tsagarakis S, Ioannides G, Tzavara I, Papavasiliou C. Megavoltage pituitary irradiation lowers but seldom leads to safe GH levels in safe GH levels in acromegaly: a long-term follow-up study. Eur J Endocrinol 1998;138:160-163.
117.Epaminonda P, Porretti S, Cappiello V, Beck-Peccoz P, Faglia G, Arosio M. Efficacy of radiotherapy in normalizing serum IGF-I, acid-labile subunit (ALS) and IGFBP-3 levels in acromegaly. Clin Endocrinol (Oxf) 2001; 55: 183-9
118.Gutt B, Hatzack C, Morrison K, Pollinger B, Schopohl J. Conventional pituitary irradiation is effective in normalising plasma IGF-I in patients with acromegaly.
Eur J Endocrinol. 2001; 144: 109-16.
119.Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992;13:221-235.
120.Moran A, Pescovitz OH. Long-term treatment of gigantism with combination octreotide and bromocriptine in a child with McCune-Albright syndrome. Endocr J 1994; 2:111-113.
121.Maheshwari HG, Prezant TR, Herman-Bonert V, et al. Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma. J Clin Endocrinol Metab 2000; 85: 3409-16.
122.Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000; 342:1171-1177.
123.van der Lely AJ, Hutson RK, Trainer PJ, et al. Long term treatment of acromegaly with pegvisomant, a growth hormone antagonist. Lancet 2001; 358:1754-1759.
124.Rix M, Laurberg P, Hoejberg AS, Brock-Jacobsen B. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl. Eur J Endocrinol. 2005;153: 195-201.
125.Beck-Peccoz P, Bruckner-Davis F, Persani L, Smallridge RC, Weintraub BD. Thyrotropin-secreting pituitary tumors. Endocr Rev 1996;17:610-638.
126.Fukuda T, Yokoyama N, Tamai M, et al. Thyrotropin secreting pituitary adenoma effectively treated with octreotide. Intern Med 1998;37:1027-1030.
127.Chanson P, Weintraub BD, Harris AG. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 1993;119:236-240.
128.Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol 1994;40:421-428
129.Kuhn JM, Arlot S, Lefebvre H, et al. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab 2000; 85: 1487-1491.
130.Freda PU, Wardlaw SL. Diagnosis and treatment of pituitary tumors. J Clin Endocrinol Metab 1999;84:3859-3866.
131.Katnelson L, Alexander JM, Klibanski A. Clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 1993;76:1089-1094.
132.Abe T, Lüdecke DK, Saeger W. Clinically nonsecreting pituitary adenomas in childhood and adolescence. Neurosurgery 1998; 42: 744-751.
133.Laws ER Jr. Transsphenoidal approach to lesions in and about the sella turcica. In Schmidek HH, Sweet WH (eds): Operative neurosurgical techniques: indications, methods and results. Grune & Stratton, Orlando, 1, 1995; pp. 283-292.
134.Jho HD, Carrau RL. Endoscopic endonasal transsphenoidal surgery: experience with 50 patients. J Neurosurg 1997;87:44-51.
135.Cappabianca P, Alfieri A, Colao A, Ferone D, Lombardi G, de Divitiis E. Endoscopic endonasal transsphenoidal approach: an additional reason in support of surgery in the management of pituitary lesions. Skull Base Surg 1999; 9:109-117.
136.Cappabianca P, Alfieri A, Colao A, et al. Endoscopic endonasal transsphenoidal surgery in recurrent and residual pituitary adenomas: technical note. Minim Invasive Neurosurg 2000; 43: 38-43
137.Cappabianca P, de Divitiis E, Alfieri A, Cavallo LM. The role of the endoscopic transsphenoidal approach in pediatric neurosurgery. Child’s Nervous Syst 2000; 16: 692-6.
138.Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton MI. Hypopituitarism following external radiotherapy for pituitary tumors in adults. QJ Med New Series. 1989; 70:145
139.Colao A, Cerbone G, Cappabianca P, et al. Effect of surgery and radiotherapy in visual and endocrine function in nonfunctioning pituitary adenomas. J Endocrinol Invest 1998; 21:284-290
140.Turner HE, Stratton IM, Byrne JV, Adams CB, Wass JA. Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation - a follow-up study. Clin Endocrinol (Oxf) 1999; 51: 281-284.
141.Colao A, Di Sarno A, Marzullo P, et al. New medical approaches in pituitary adenomas. Horm Res 2000; 53:76-87
142.Colao A, Ferone D, Lastoria S, et al. Hormone levels and tumor size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically nonfunctioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-Methoxybenzamide. Clin Endocrinol 2000; 52:437-445.
143.Pivonello R, Matrone C, Filippella M, et al. Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab. 2004; 89: 1674-83.